About Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3) is a protein
from Homo sapiens identified by UniProt accession
P16520, 340 residues long.
MolForge cross-references it against 0 known binders and
176 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 |
| UniProt accession | P16520 |
| Gene | GNB3 |
| Organism | Homo sapiens |
| Length | 340 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (176)
Diseases linked to this target (Open Targets).
- congenital stationary night blindness 1H · score 0.68
- congenital stationary night blindness · score 0.37
- endometrial cancer · score 0.28
- breast adenocarcinoma · score 0.28
- head and neck squamous cell carcinoma · score 0.26
- Myopia · score 0.24
- lung adenocarcinoma · score 0.23
- Abnormality of refraction · score 0.23
- refractive error · score 0.21
- refractive error measurement · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P16520-F1 | alphafold | PREDICTED | 97.18 | — |
Amino-acid sequence (340 residues)
MGEMEQLRQE AEQLKKQIAD ARKACADVTL AELVSGLEVV GRVQMRTRRT LRGHLAKIYA MHWATDSKLL VSASQDGKLI VWDSYTTNKV HAIPLRSSWV MTCAYAPSGN FVACGGLDNM CSIYNLKSRE GNVKVSRELS AHTGYLSCCR FLDDNNIVTS SGDTTCALWD IETGQQKTVF VGHTGDCMSL AVSPDFNLFI SGACDASAKL WDVREGTCRQ TFTGHESDIN AICFFPNGEA ICTGSDDASC RLFDLRADQE LICFSHESII CGITSVAFSL SGRLLFAGYD DFNCNVWDSM KSERVGILSG HDNRVSCLGV TADGMAVATG SWDSFLKIWN
Explore Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets